Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S Nair, Sara K Silbert, Kai Rejeski, Karilynn A Wilson, Adam Joseph Lamble, Yannis K. Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin J. Curran, Rebecca A Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N Shah

Blood blood.2024025910.

https://doi.org/10.1182/blood.2024025910

Published: 2024

Includes: Supplemental data

Journal Articles

Proliferation of a Novel CD3 neg Hyperactivated T-Cell Population Characterizes Adult Hemophagocytic Lymphohistiocytosis and Associates with Disease Activity

Joseph M. Rocco, Elizabeth Laidlaw, Bonnie Yates, Brett Schroeder, Emily Limerick, William T. Johnson, Joseph H. Oved, Frances Galindo, Whitney Ewing, Courtney Fitzhugh, Maura Manion, Andrea Lisco, Steven Holland, Nirali N. Shah, Irini Sereti

Blood (2024) 144 (Supplement 1): 5382.

https://doi.org/10.1182/blood-2024-210363

Published: 2024

Journal Articles

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Brynn B. Duncan, Sara K. Silbert, Alexander W. Rankin, Bonnie Yates, Lauren Little, Toni Foley, Hao-Wei Wang, Constance M. Yuan, Dana I. Delgado Colon, Yanyu Wang, Jon Inglefield, John A Ligon, Hannah W. Song, Steven L. Highfill, Haneen Shalabi, David F. Stroncek, Naomi Taylor, Nirali N. Shah

Blood (2024) 144 (Supplement 1): 680.

https://doi.org/10.1182/blood-2024-198259

Published: 2024

Journal Articles

Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro , In Vivo , and Ex Vivo Anti-Leukemia Activity

Tommaso Balestra, Camilo Arenas Merizalde, Robert K Chen, John Roach, Brian Bowser, Rachelle Salomon, Anthony Welch, Bonnie Yates, Kristin Schaller, Michael R Verneris, Susanne H.C. Baumeister, Emily M. Hsieh, M. Eric Kohler, Katherine Tarlock, Steven M. Devine, Richard Aplenc, Nirali N. Shah, Terry J Fry, Sarah K. Tasian

Blood (2024) 144 (Supplement 1): 369.

https://doi.org/10.1182/blood-2024-211517

Published: 2024

Journal Articles

Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

Alexandra Dreyzin, Yihua Cai, Kyu Lee Han, Michaela Prochazkova, Jennifer Webb, Keri Toner, Kathryn Bushnell, Bonnie Yates, Ping Jin, David F. Stroncek, Nirali N. Shah

Blood (2024) 144 (Supplement 1): 4853.

https://doi.org/10.1182/blood-2024-199264

Published: 2024

Journal Articles

PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Jacinta Davis, JuanCarlos Balandrán, Katharina Hayer, Sisi Zheng, Zhiwei Ang, Evelyn Liu, Bonnie Yates, Nirali N. Shah, Iannis Aifantis, Andrei Thomas-Tikhonenko

Blood (2024) 144 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2024-208185

Published: 2024

Journal Articles

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Blood (2023) 142 (Supplement 1): 771.

https://doi.org/10.1182/blood-2023-179667

Published: 2023

Journal Articles

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

Blood (2022) 140 (Supplement 1): 3480–3482.

https://doi.org/10.1182/blood-2022-169102

Published: 2022

Journal Articles

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Blood (2022) 140 (5): 451–463.

https://doi.org/10.1182/blood.2022015795

Published: 2022

Includes: Supplemental data

Journal Articles

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Blood (2021) 138 (24): 2469–2484.

https://doi.org/10.1182/blood.2021011898

Published: 2021

Includes: Supplemental data

Journal Articles

Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia

Sara K. Silbert, Elizabeth M. Holland, Seth M. Steinberg, Lauren Little, Toni Foley, Haneen Shalabi, Bonnie Yates, Nirali N. Shah

Blood (2021) 138 (Supplement 1): 1731.

https://doi.org/10.1182/blood-2021-146979

Published: 2021

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Agne Taraseviciute, MD, Seth M. Steinberg, PhD, Regina M. Myers, MD, Lia Gore, MD, Adam J. Lamble, MD, Patrick A. Brown, MD, Jennifer Sheppard, Bonnie Yates, NP, Perry Chung, MD, Lee Chen, Colleen Annesley, MD, Deepa Bhojwani, MD, Theodore W. Laetsch, MD, Rebecca A Gardner, MD, Susan R. Rheingold, MD, Michael A Pulsipher, MD, Nirali N. Shah, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139260

Published: 2020

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response

Bonnie Yates, RN, Haneen Shalabi, DO, Dalia Salem, MD, Cynthia Delbrook, RN, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Nirali N. Shah, MD

Blood (2018) 132 (Supplement 1): 282.

https://doi.org/10.1182/blood-2018-99-119621

Published: 2018

Journal Articles

Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome

Nirali N Shah, MD, Haneen Shalabi, DO, Bonnie Yates, RN, Eli Kane, Alina Dulau-Florea, MD, Anne Cullinane, BS, Cynthia Delbrook, RN, Michael Ombrello, MD, Amanda Ombrello, MD, Jay Nelson Lozier, MD PhD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 1277.

https://doi.org/10.1182/blood.V130.Suppl_1.1277.1277

Published: 2017

Journal Articles

CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort

Nirali N Shah, MD, Steven L Highfill, PhD, Haneen Shalabi, DO, Bonnie Yates, RN, Eli Kane, Vicki Fellowes, Cynthia Delbrook, RN, Jiaqiang Ren, MD PhD, Jianjian Jin, David Stroncek, MD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 809.

https://doi.org/10.1182/blood.V130.Suppl_1.809.809

Published: 2017

Journal Articles

Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy

Haneen Shalabi, DO, Nirali N Shah, MD, Terry J. Fry, MD, Bonnie Yates, RN, Cynthia Delbrook, RN, Constance Yuan, Maryalice Stetler-Stevenson, Sneha Ramakrishna, MD

Blood (2017) 130 (Supplement 1): 3889.

https://doi.org/10.1182/blood.V130.Suppl_1.3889.3889

Published: 2017

Journal Articles

Chimeric Antigen Receptor Induced Cytopenia Differs from Chemotherapy Induced Myelosuppression

Haneen Shalabi, DO, Nirali N Shah, MD, Terry J. Fry, MD, Bonnie Yates, RN, Cynthia Delbrook, RN

Blood (2017) 130 (Supplement 1): 5048.

https://doi.org/10.1182/blood.V130.Suppl_1.5048.5048

Published: 2017

Journal Articles

A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy

Haneen Shalabi, DO, Pamela L Wolters, PhD, Staci Martin, PhD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Daniel W. Lee, III, MD, Crystal L. Mackall, MD, Terry J Fry, MD, Nirali N Shah, MD

Blood (2016) 128 (22): 1625.

https://doi.org/10.1182/blood.V128.22.1625.1625

Published: 2016

NARROW

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Proliferation of a Novel CD3 neg Hyperactivated T-Cell Population Characterizes Adult Hemophagocytic Lymphohistiocytosis and Associates with Disease Activity

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro , In Vivo , and Ex Vivo Anti-Leukemia Activity

Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML: Dose-Escalation Results from a Phase I/II Multicenter Trial

Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells

Adverse Events Following CAR T-Cell Therapy: A Single Institution Retrospective Analysis of Toxicities Following CAR T-Cell Therapy for Children and Young Adults with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Infectious Complications Associated with CAR T-Cell Therapy

Sequential CD22 Targeting Impacts CD22 CAR-T Cell Response

Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome

CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort

Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy

Chimeric Antigen Receptor Induced Cytopenia Differs from Chemotherapy Induced Myelosuppression

A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only